Home›Research›Compare›Pramlintide vs Semaglutide
Peptide ComparisonPramlintide vs Semaglutide
Both are Metabolic peptides.
Pramlintide
Symlin
Half-life: ~48 minutes
No providers listed yet
Semaglutide
Ozempic
Half-life: ~7 days (once-weekly dosing)
801 providers listed
Semaglutide carries stronger published evidence (RCT, 9 key studies) than Pramlintide (RCT, 4); both are research compounds.
Pramlintide
Evidence
Half-life
~48 minutes
Semaglutide
Evidence
Half-life
~7 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Semaglutide |
| Less frequent dosing (longer half-life) | Semaglutide |
| Oral administration option | Semaglutide |
| More provider options (0 vs 801) | Semaglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Pramlintide
Semaglutide
Pramlintide
Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…
Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…
Pramlintide.
Semaglutide
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
+5 more
About Pramlintide
Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety
About Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Pramlintide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Semaglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Pramlintide
Not enough vendor pricing yet.
Semaglutide
Where to source these peptides
Pramlintide
Browse directory →
Providers offeringSemaglutide
801 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Pramlintide vs Semaglutide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/pramlintide/semaglutide